CN108299561A - A kind of PD-1 nano antibodies and its cloning expression method and application - Google Patents

A kind of PD-1 nano antibodies and its cloning expression method and application Download PDF

Info

Publication number
CN108299561A
CN108299561A CN201810002873.4A CN201810002873A CN108299561A CN 108299561 A CN108299561 A CN 108299561A CN 201810002873 A CN201810002873 A CN 201810002873A CN 108299561 A CN108299561 A CN 108299561A
Authority
CN
China
Prior art keywords
seq
nano
nano antibodies
cell
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201810002873.4A
Other languages
Chinese (zh)
Other versions
CN108299561B (en
Inventor
熊盛
邓颖莎
陈纯
谢秋玲
卢加
李军
洪岸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan University
University of Jinan
Original Assignee
Jinan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan University filed Critical Jinan University
Priority to CN201810002873.4A priority Critical patent/CN108299561B/en
Publication of CN108299561A publication Critical patent/CN108299561A/en
Application granted granted Critical
Publication of CN108299561B publication Critical patent/CN108299561B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention discloses a kind of 1 nano antibodies of PD and its cloning expression method and applications.The 1 nano antibody molecular weight of PD is small, high specificity, affinity are high, can inhibit the interaction between 1 molecule of PD L1 and PD, and can specific recognition cell surface native conformation PD 1, block PD L1 to be combined to keep T cell activity with PD 1;With the identical binding ability with 1 monoclonal antibodies of PD (IgG whole antibodies);And the state that activating T cell can be reversed to be inhibited by PD L1.Meanwhile compared with 1 monoclonal antibodies of PD, the relative activity higher of nano antibody of the present invention after same high temperature process, thermal stability is more preferable, has the potentiality for being developed into immunologic test point inhibitor.Meanwhile nano antibody cloning expression method yield of the invention is higher, obtains purity of protein up to 93% or more, preparation method is simple, of low cost, has a good application prospect in the preparation of antitumor drugs.

Description

A kind of PD-1 nano antibodies and its cloning expression method and application
Technical field
The invention belongs to biomedicine technical field, more particularly to a kind of PD-1 nano antibodies and its cloning expression method with Using.
Background technology
Tumour is one of Global mortality highest disease, seriously threatens human health;In addition to operation, radiotherapy, tumour Therapy further include:Chemotherapy, hormonotherapy, targeted drug therapy and tumour immunotherapy.From 2013《Science》 After tumour immunotherapy is classified as year most important scientific breakthrough by magazine, tumour immunotherapy is more concerned in recent years.
Targeting blocking immunity checkpoint tumour immunotherapy has been increasingly becoming the focus of attention of oncotherapy, from 2014, FDA successively ratifies the Keytruda of Mo Shadong and the Opdivo of Bristol Myers Squibb for since treating melanoma, having targeted journey The antibody of sequence death molecule 1 (programmed death-1, PD-1, CD279) clinically illustrates excellent, wide spectrum anti- Tumor promotion so that PD-1 inhibitor becomes the medicine of most foreground in current immunotherapy of tumors.After T cell is activated PD-1 expression is induced, with its ligand PD-L1 (programmed cell death 1ligand 1) or PD-L2 (programmed 1 ligand 2, PD-L2 of cell death) combine after, phosphorylation, Protein-tyrosine-phosphatase occur for the tyrosine in the areas ITSM Molecule is recruited so that and the effector molecule dephosphorylation in downstream activates PD-1/PD-Ls signal paths, negative regulator signal of transduceing, Inhibit T cell activation, lowers immune response.Under normal circumstances, which plays key work in terms of maintaining T cell stable state With.But in tumor microenvironment, tumor-infiltrating lymphocytes, tumor specific T cells and some relevant T cell surfaces of damage Height expression PD-1 molecules, after tumor surface PD-L1 is combined with T cell surface PD-1, transmit inhibition signal, keep T cell active It lowers, to inhibit immune response of the body to tumour, tumour is caused to generate immunologic escape.Since PD-1, PD-L1 widely join With to tumor immune escape, therefore, the activity of the releasable T Lymphocvte Killers tumour of PD-1/PD-Ls accesses is targeted and blocks, To effectively inhibit tumour progression.
At present listing or granted clinical test PD-1 antibody be monoclonal antibody (monoclonal anbibody, MAb) (Fig. 1), monoclonal IgG whole antibodies have that tissue permeability is weak, immunogenicity is stronger, the inadequate natural endowments such as of high cost, in addition, The whole antibody long half time for targeting PD-1, there is the potential risk for causing body excessive immune.
1993, Hamers Casterman etc. isolated natural deletions light chain, only containing heavy chain from camel serum Camel antibodies are named as heavy chain antibody (heavy-chain antibody, HCAb).And VHH (variable domain of Heavy chain of heavy-chain antibody) be on heavy chain antibody can molecule of the antigen binding structural domain, be logical The variable region for crossing technique for gene engineering clone's heavy chain antibody, obtains the single domain antibody being only made of a heavy chain variable region.Because VHH crystal diameters 2.5nm, long 4nm, so VHH is also referred to as nano antibody (Nanobody, Nb).Nano antibody has high parent With power, high stability, highly-water-soluble, high antigen binding, high expression, strong tissue permeability, low immunogenicity and half-life period Short feature has unique advantage in therapeutic antibodies course of drug development, and there has been no the PD-1 nanometers of tool functional activity at present The report of antibody drug.
Invention content
The primary purpose of the present invention is that the shortcomings that overcoming the prior art and deficiency, provide a kind of new anti-PD-1 antibody (nano antibody).
Another object of the present invention is to provide the cloning expression methods of the PD-1 nano antibodies.
Another object of the present invention is to provide the application of the PD-1 nano antibodies.
The purpose of the invention is achieved by the following technical solution:
A kind of nano antibody of Programmed death 1 (PD-1 nano antibodies), including by framework region FR (framework Region) and complementary determining region CDR (complementarity-determining regions) composition variable region structure Domain, the Variable domain include CDR1, CDR2 and CDR3 selected from the following:
(1) CDR1 shown in SEQ ID No.1 or SEQ ID No.2,
(2) CDR2 shown in SEQ ID No.3,
(3) CDR3 shown in SEQ ID No.4 or SEQ ID No.5.
The Variable domain includes CDR1, CDR2 and CDR3 selected from the following:
(1) shown in CDR2 and SEQ ID No.4 shown in CDR1 shown in SEQ ID No.1, SEQ ID No.3 CDR3;
(2) shown in CDR2 and SEQ ID No.5 shown in CDR1 shown in SEQ ID No.2, SEQ ID No.3 CDR3。
Described framework region FR FR1, FR2, FR3 and the FR4 selected from the group below:
(1) FR1 shown in SEQ ID No.6;
(2) FR2 shown in SEQ ID No.7 or SEQ ID No.8;
(3) FR3 shown in SEQ ID No.9;
(4) FR4 shown in SEQ ID No.10.
The amino acid sequence of the PD-1 nano antibodies is selected from shown in following any sequence:
QVQLQESGGGSVQAGGSLRLSCVASGFTHLRYSMGWFRQVLDKEREGVAAIGGDGRTSYADSVKGRFTIFKDNAKNT LYLDMNSLNPEDTAMYYCAAAVLLDGSFSLLAPLVPYKYDYWGQGTQVTVSS (SEQ ID No.11) or
QVQLQESGGGSVQAGGSLRLSCVASGLTYLRYSMGWFRQVPDKEREGVAAIGGDGRTSYADSVKGRFTIFKDNAKNT LYLDMNSLNPEDTAMYYCAAAVLLDGSFSLLAPLTPYKYDYWGQGTQVTVSS(SEQ ID No.12);
Start on the left of above-mentioned amino acid sequence as aminoterminal, right side is terminated as c-terminus, and sequence is:No underscore Sequence is framework region respectively:FR1~FR4;Underscore is complementary determining region, CDR1~CDR3.
The PD-1 nano antibodies include and any amino acid sequence shown in SEQ ID No.11 or SEQ ID No.12 Row have at least 90%, preferably at least 95%, the more preferably at least amino acid sequence of 99% sequence identity.
Any amino acid sequence as shown in SEQ ID No.11 or SEQ ID No.12 is by substitution, missing or addition The amino acid sequence of one or several amino acid.
The substitution is preferably compared with any amino acid sequence shown in SEQ ID No.11 or SEQ ID No.12 Including one or more amino acid substitutions, preferably conserved amino acid replace.For example, including 1,2,3,4,5,6,7,8,9 or 10 Conserved amino acid replaces.
The nucleotide sequence of the coding PD-1 nano antibody amino acid sequences, (1) chosen from the followings, (2) or (3):
(1) nucleotide sequence as shown in SEQ ID No.13 or SEQ ID No.14;
(2) different from nucleotide sequence shown in SEQ ID No.13 or SEQ ID No.14, but encode such as SEQ ID The nucleotide sequence of amino acid sequence shown in No.11 or SEQ ID No.12;
(3) with the nucleotide sequence of (1) or (2) any one of them nucleotide sequence complementation.
The PD-1 nano antibodies have at least one of following characteristics:
(1) PD-1 and PD-L1 is blocked to combine;
(2) T cell inactivated state caused by PD-L1 is reversed;
(3) inhibit tumour growth.
A kind of nucleic acid molecules encode the PD-1 nano antibodies.
A kind of recombinant expression carrier, the weight of the nucleotide sequence containing the coding PD-1 nano antibody amino acid sequences Group expression vector.
The expression vector be phagemid vector or can encode the PD-1 nano antibodies amino acid sequence other Bacterial expression vector and Yeast expression carrier, eukaryotic expression vector.
The phagemid vector is preferably phasmid pMECS.
A kind of host cell has converted and has incorporated the coding institute on the recombinant expression carrier or genome The host cell and its progeny cell of the nucleotide sequence for the PD-1 nano antibodies stated.
The host cell and its progeny cell refer to bacterial cell, fungal cell, zooblast or plant cell and The offspring of these host cells.
The host cell is preferably Escherichia coli;Further preferably E.coli WK6.
The cloning expression method of the PD-1 nano antibodies, includes the following steps:
The nucleotide sequence of the coding PD-1 nano antibodies is cloned into expression vector, structure recombinant expression carries Body;The recombinant expression carrier is transferred in expression system again and is expressed;Substep purifying is carried out to destination protein, finally To the PD-1 nano antibodies.
Application of the PD-1 nano antibodies in preparing prevention and/or treating cancer drug.
The prevention and/or treating cancer drug is preferably immunologic test point inhibitor medicaments.
The drug can be pharmaceutical composition, including pharmaceutically acceptable carrier.
The drug can also be applied in combination therapy, i.e., be combined with other medicaments.For example, combination therapy can wrap Include at least one other antitumor drugs of PD-1 nano antibodies joint of the present invention.
The present invention has the following advantages and effects with respect to the prior art:
1. the PD-1 nano antibody molecular weight small (about 18kDa) of the present invention, high specificity, affinity are high, PD-L1 can be inhibited With the interaction between PD-1 molecules, and can specific recognition cell surface native conformation PD-1, block PD-L1 and PD-1 to tie It closes to keep T cell active;With binding ability identical with PD-1mAb.It is of the invention in vitro in PBMC Activation models PD-1 nano antibodies can reverse the state that activating T cell is inhibited by PD-L1, raise the expression of IFN-γ.
2. compared with PD-1 monoclonal antibodies (present invention selects to be commercialized the anti-PD-1 monoclonal antibodies of mouse as a contrast), this The nano antibody of invention (is abbreviated as NbPD-1, the Nb2 and Nb3 as shown in SEQ ID No.11 or SEQ ID No.12) it is special Property is suitable therewith, and the relative activity higher of nano antibody of the invention after same high temperature process, thermal stability are more preferable; With the potentiality for being developed into immunologic test point inhibitor, material is provided for follow-up oncotherapy drug candidate.
3. the PD-1 nano antibody cloning expression methods of the present invention, after test tube or shaking flask culture, yield is up to 3.6mg/L ~4.5mg/L, purity of protein are more than 93%, and preparation method is simple, of low cost, and future can advanced optimize condition of culture and put Greatly, to obtain higher yield.
4. the present invention successfully constructs the eukaryon expression plasmid of encoding human PD-1 extracellular fragments (PD-1ECD) recombinant protein, lead to It is overexpressed purifying, purity is obtained and is more than 90%, the PD-1ECD recombinant proteins with functional activity, and as antigen, from great Rong Measure the nanometer that the small two strain molecule amounts that filtered out in natural bacteriophage nano antibody library, high specificity, affinity are high, thermal stability is good Antibody Nb2 and Nb3.
Description of the drawings
Fig. 1 is the sketch map of PD-1 antibody present Research in the prior art.
Fig. 2 is the affinity determination curve graph of PD-1 nano antibodies Nb2 and Nb3.
Fig. 3 is the thermal stability analysis figure of PD-1 nano antibody Nb2 and Nb3 and commercially available PD-1 monoclonal antibodies;Wherein, A: 25 DEG C of processing;B:37 DEG C of processing;C:60 DEG C of processing;D:90 DEG C of processing.
Fig. 4 is the interpretation of result figure of the competion experiment of PD-1 nano antibody Nb2 and Nb3 and PD-1mAb;Control For negative control.
Fig. 5 is the interpretation of result figure of the competion experiment of PD-1 nano antibody Nb2 and Nb3 and PD-L1;Control is Negative control.
Fig. 6 is PD-1 nano antibody Nb2 and Nb3 and HEK 293T/PD-1 cell membrane surface PD-1 molecular binding events point Analysis figure;Wherein, A:PD-1mAb groups;B:2 groups of Nb;C:3 groups of Nb;D:For PD-1mAb groups, the sample peak of 3 groups of 2 groups of Nb and Nb Graphic data overlap-add procedure Integrated comparative.
Fig. 7 is that PD-1 nano antibody Nb2 and Nb3 inhibits the active barrier effect analysis chart of T cell to PD-L1.
Specific implementation mode
Present invention will now be described in further detail with reference to the embodiments and the accompanying drawings, but embodiments of the present invention are unlimited In this.
The preparation of related reagent in embodiment:
1.RPMI 1640/FBS culture mediums:89mL RPMI 1640Medium, 10mL FBS, 1mL is dual anti-, 1 μ g Human IL-2 is mixed well, and 4 DEG C save backup, one week term of validity.
2.DMEM/FBS culture mediums:445mL DMEM, 50mL FBS, 5mL is dual anti-, mixes well, and 4 DEG C save backup.
3.WST-8 solution:1.8mg 1-methoxy PMS, 0.1158g WST-8,0.351g NaCl, are completely dissolved in In 40mL ultra-pure waters, 0.45 μm of membrane filtration, packing, -20 DEG C be kept in dark place it is spare.
4.PEG/NaCl solution:PEG6000 200g, NaCl 146.1g, ultra-pure water fully dissolve, and are settled to 1L, 121 DEG C Sterilize 20min, and 4 DEG C save backup.
5.TES solution:0.146g EDTA (final concentration 0.5mM), 171.15g sucrose (final concentration 0.5M), Tris-HCl (0.2M, pH 8.0) fully dissolves, and is settled to 1L, 0.22 μm of filter membrane degerming, 4 DEG C save backup.
Expression, purifying and identification of the 1 people's PD-1 Extracellular domain proteins of embodiment in eukaryocyte
According to PD-1 extracellular fragments (PD-1ECD) gene order (NCBI Gene ID:5133) and with reference to pCMV (it is purchased from Shanghai Green skies Bioisystech Co., Ltd) multiple cloning sites information, designs suitable primer and Nhe I, BamH I digestions position is added Point and 6XHis labels use TaKaRa using pEZ-M02-PD-1 (being purchased from Guangzhou FulenGen Co., Ltd.) as template PrimerSTAR HS DNA Polymerase carry out PCR reactions, PCR product is examined through 1% agarose gel electrophoresis, There is a clearly amplified band above 500bp, is consistent with expected size 546bp.Use the FastDigest of Fermentas companies Nhe I and BamH I carry out double digestion to pCMV carriers and the PD-1ECD genes amplified, are inserted into pCMV plasmids, structure coding The carrier for expression of eukaryon pCMV-PD-1ECD of PD-1ECD recombinant proteins.PCMV-PD-1ECD is imported into HEK by rotaring dyeing technology 293F cells (being purchased from Thermo Fisher, USA) transient expression PD-1ECD recombinant proteins, crude protein pass through the affine layers of Ni-NTA PD-1ECD recombinant proteins are obtained after analysis column (being purchased from GE Healthcare, USA) purifying, concentration.Pass through SEC-HPLC and ELISA Testing and appraisal PD-1ECD recombinant protein purity is more than 90%, and has in conjunction with activity with mouse PD-1mAb, PD-L1, can be used as antigen Albumen is for subsequently screening nano antibody work.
Embodiment 2PD-1 nano antibodies screen
1.VCSM13 helper phages prepare and titer determination
Take the VCSM13 (being purchased from Agilent Technologies) of different dilutions that the E.coli TG1 newly expanded are added In (purchased from Chinese plasmid vector bacterium cell gene collection) bacterium solution, it is incubated at room temperature 15min.Mixture respectively adds 3mL liquid Change the LB top agar (less than 50 DEG C), LB tablets are poured into after mixing, 37 DEG C are incubated overnight, and calculate plaque number and to obtain Single plaque.The E.coli TG1 bacterium solutions that the single plaque of picking is newly expanded to 5mL, after 37 DEG C of shaken cultivation 3h, transfer training It supports in object to 100mL 2YT fluid nutrient mediums (the 70 μ g/mL containing kanamycins), 37 DEG C of shaken cultivations are stayed overnight.Culture is collected by centrifugation 7%DMSO, -20 DEG C or -80 DEG C preservations are added in supernatant, centrifuging and taking supernatant after 70 DEG C of water-baths.
2. the natural bacteriophage nano antibody amplified library of large capacity
Taking 100 μ L large capacities natural bacteriophage nano antibody libraries, (phasmid used is pMECS, the nano antibody library Yan J, Wang P, Zhu M, Li G are had been disclosed in, E,Xiong S,Wan Y.Characterization and applications of Nanobodies against human procalcitonin selected from a novelNanobody phage display library.J Nanobiotechnology.2015May 6;13(1):33, Can be found in "VHH library construction " chapters and sections) it is added the E.Coli TG1 bacterium solutions that newly expand of 2mL, 37 After DEG C standing, adds 8mL 2 × YT/Amp-Glu fluid nutrient mediums, after 37 DEG C of shaken cultivation 30min, add 1mL helper phages Body VCSM13 shakes up, and is stored at room temperature 30min.Low speed room temperature centrifuges, and precipitates appropriate 2 × YT/Amp-Kan Liquid Cultures base weight Outstanding, 37 DEG C of shaken cultivations are stayed overnight.Next day recycles culture solution, PEG precipitating phages, through 0.22 μm of filter mistake after 1 × PBS resuspensions Filter, the fresh phage library preparation solution being prepared are tested for subsequent elutriation.
3. large capacity natural bacteriophage nano antibody library is eluriated
It is screened (6.68 × 10 in natural phage library using display technique of bacteriophage11CFU/Total) with PD-1 extracellular fragments The bacteriophage of specific binding.
With 100mM NaHCO3Dilute PD-1ECD antigens (i.e. PD-1ECD recombinant proteins made from embodiment 1, similarly hereinafter) extremely Suitable concentration is added in 96 hole elisa Plates, is coated with 4~6 holes, overnight in 4 DEG C.Next day is de- with 0.05%PBST board-washings 1 time, 2% After fat milk room temperature closes 2h, PBST board-washings 2 times.The phage library preparation solution that appropriate step 2 obtains is taken, is bitten with PBS dilutions Cell concentration is to 1 × 1012Phage/mL obtains phage library dilution.100 μ L phage library dilutions are added per hole, Phage library dilution is sucked after incubation at room temperature 1h, and (often wheel is eluriated to eluriate result by upper wheel and adjust and be washed for PBST board-washings 5~20 times Plate number).The 100mM triethylamine solutions of Fresh are added, eluent is sucked out after being stored at room temperature 10min, 1M Tris- are added HCl is neutralized, and obtains the phage antibody for being incorporated into solid phase.Take 600 μ L phage antibodies that the E.Coli TG1 that 2mL is newly expanded are added Bacterium solution mixing, 37 DEG C of standings, bacterium solution after being infected take out appropriate measurement CFU, 2 × YT/ of 8mL are added after infection in bacterium solution 1mL helper phages VCSM13 is added after 37 DEG C of shaken cultivations and shakes up, is stored at room temperature 30min for Amp-Glu culture mediums.800×g 10min is centrifuged, precipitation is resuspended in appropriate 2 × YT/Amp-Kan culture mediums, and 37 DEG C of shaken cultivations are stayed overnight.Third day recycles culture solution, PEG precipitating phages, 1 × PBS are filtered through 0.22 μm of filter after being resuspended, are tested for subsequent elutriation.Last wheel is eluriated, and 4 DEG C preserve calculate library size tablet (30 < monoclonals < 300) or a dilution tablet is spare thereon.
4.PD-1 extracellular fragment bacteriophage nano antibodies library enrichment verification (Phage-ELISA method)
PD-1ECD is stayed overnight with the holes 100ng/ coated elisa plate, with 100mM NaHCO3As negative control, next day board-washing 1 It is secondary, after 2% skim milk room temperature closes 2h, PBST board-washings 2 times.Often wheel is eluriated the phage library solution prepared and is diluted with 1 × PBS To 2 × 1011Phage/mL, with 2% skim milk 1:1 mixing, the mixed liquor as often taken turns.The mixed liquor often taken turns is with 100 holes μ L/ Antigen hole and its corresponding nonreactive foramen primum is added, is incubated at room temperature 1h.Mixed liquor is sucked out, abandons in bleaching liquid, after PBST board-washings 5 times Anti-M13 Bacteriophage antibody (HRP) (being purchased from Divine Land Yi Qiao, Beijing biotechnology company) are added to carry out instead It answers, is stored at room temperature 1h.Antibody diluent is sucked out, TMB colour developings are added after board-washing, sulfuric acid terminates, and microplate reader measures OD450nm.With OD450nm(antigen hole-nonreactive foramen primum) maps, it can be seen that light absorption value is gradually reinforced after often wheel is eluriated, that is, the bacteriophage for being directed to antigen receives Meter Kang Ti is enriched with.The results show that three-wheel specifically binds PD-1ECD bacteriophage after eluriating obviously is enriched with.
5.PD-1 extracellular fragment bacteriophage nano antibody library screening
1mL TB/Amp culture mediums are added per hole for 96 hole deep-well plates;It is selected at random per hole and last wheel guarantor in step 3 is added Deposit a monoclonal on tablet.Standby LB/Amp-Glu tablets, each corresponding region of clone, 37 DEG C are incubated overnight, 4 DEG C of guarantors It deposits.IPTG (final concentration 1mM) is added in 96 hole deep-well plates, 37 DEG C of shaken cultivation 3h after inoculation, and 28 DEG C of shaken cultivations are stayed overnight, simultaneously It is coated with two piece of 96 orifice plate, antigen hole and nonreactive foramen primum are fifty-fifty on same ELISA Plate, and 4 DEG C overnight.Next day, 0.05%PBST board-washings 1 It is secondary, close 2h with 2% skim milk room temperature.Supernatant is abandoned in 96 hole deep-well plates centrifugations, after TES is resuspended, 4 DEG C of oscillation 2h, then add per hole Enter 300 μ L TES/4,4 DEG C vibrate 2h, centrifuging and taking supernatant.96 orifice plates suck confining liquid, with 0.05%PBST board-washings 2 times.Deep hole 96 orifice plates of coating PD-1ECD antigens, 100 holes μ L/ are added in plate supernatant, while 100 holes μ L/ are also added in corresponding nonreactive foramen primum, It is incubated at room temperature 1h.Incubating Solution is sucked out, Anti-6X His tag antibody (HRP) (being purchased from Abmart) are added in PBST board-washings It is reacted, is incubated at room temperature 1h;Antibody diluent is sucked out, TMB colour developings are added after board-washing, microplate reader measures OD450nm.Light absorption value More than 1, and higher than twice of same periplasmic extract nonreactive foramen primum or more, regard as positive colony;By ELISA Preliminary Identifications, 22 possible positive antibody clones are obtained altogether.The access 5mL LB/Amp cultures of positive colony corresponding region thalline on tablet In base, 37 DEG C of shaken cultivations to suitable concentration.Illustrate with reference to kit, mini-scale plasmid extraction process prepares pMECS-NbPD-1Plasmid, Inspection is sequenced.
The DNA sequence dna obtained after 22 positive antibody clones are sequenced, amino acid is obtained with Bioedit software translations Sequence.According to international immunogenetics information system (IMGT) to the framework region (framework region, FR) of protein sequence Distinguished with antibody identification region (complementarity-determining regions, CDR), CDR1, CDR2, The clone of CDR3 sequence all sames is considered as same antibody strain, and the different clone of CDR sequence is considered as different antibodies strain, is finally obtained 6 positive antibodies clone (number is Nb1~6), their CDR region amino acid sequence has differences, wherein 2 plants of nano antibodies Amino acid sequence feature is shown in Table 1.
The primary structural sequence feature of 1 anti-PD-1 extracellular fragments nano antibody of table
The expression and purification of embodiment 3PD-1 nano antibodies
1.E.coli WK6 electricity turns competence preparation
E.coli WK6 (purchased from Chinese plasmid vector bacterium cell gene collection) seed liquor of -80 DEG C of preservations is taken to connect After kind amplification, it is seeded in 250mL LB culture mediums in the ratio of 1% (v/v), 37 DEG C of shaken cultivations to bacterium solution OD600=0.35 ~0.4, ice bath 30min.4 DEG C of centrifugations, precipitation are added sterile ultra-pure water and are resuspended, and repeated centrifugation is primary, and cold 10% nothings of 20mL are added Bacterial sediment is resuspended in bacterium glycerite.After 4 DEG C of centrifugations, supernatant is carefully sucked out, it is heavy that thalline is resuspended in cold 10% sterile glycerol solutions of 1mL It forms sediment, is dispensed into the sterilizing 1.5mL EP pipes of precooling, -80 DEG C save backup.
2.pMECS-Nb PD-1Electrotransformation
Electric revolving cup is pre-chilled on ice, WK6 competent cells made from step 1 is taken out, in melting 10min on ice.Take 100ng pMECS-Nb PD-1Plasmid storing solution (obtains in embodiment 1 " 5.PD-1 extracellular fragment bacteriophage nano antibodies library screening " pMECS-NbPD-1Plasmid), mixing in WK6 competence bacterium solutions is added, after turning according to the parameter electricity that electroporation is recommended, is added immediately Mixture is sucked out in 1mL SOC culture medium mixings, is placed in 37 DEG C of shaken cultivation 20min, and 1 μ L Amp storing solutions are added, continue to cultivate 20min.Appropriate bacterium solution is taken to be coated on LB/Amp agar plate surfaces, 37 DEG C of culture 12h~16h detect transfection efficiency.Next day, It chooses monoclonal amplification and freezes strain.
The WK6 expression of 3.PD-1 nano antibodies
The strain frozen is inoculated into 10mL LB-Amp culture mediums, in 37 DEG C of shaken cultivation 7h, as bacterium seed liquor. Bacterium seed liquor is seeded in the ratio of 1% (v/v) in TB/Amp-Glu-Mg Shake flask mediums, 37 DEG C, shaken cultivation to conjunction After suitable density, addition IPTG (final concentration 1mM), 28 DEG C, 200rpm overnight incubations.Next day, centrifugation are abandoned supernatant, are washed with 1 × PBS After twice of thalline, -20 DEG C of preservations of bacterial sediment.
4. permeability evolution extracts thalline periplasmic space total protein
Thalline thaw at RT 30min, the TES resuspension that step 3 obtains, 4 DEG C, 200rpm vibrates 1~6h.It adds twice The TES/4 of TES volumes continues 4 DEG C, and 200rpm vibrates 2h or stays overnight.11,300 × g, 4 DEG C of centrifugation 30min, takes supernatant.It is added 0.2M MgCl2Solution, until final concentration of 1mM, obtains thalline periplasmic space total protein.
5.PD-1 nano antibodies purify
Ni SepharoseTMExcel (being purchased from GE Healthcare) dress column, pillar specification is 1.6 × 20cm, column bed body Product is 5mL.After Ni-NTA affinity columns being balanced with 1 × PBS (pH 7.4), 1mL/min loadings (the thalline week that step 4 obtains Matter space total protein).After 1 × PBS (pH 7.4) multiple equilibria, albumen is eluted with 20mM imidazoles, collecting eluting peak, (PD-1 nanometers anti- Body).The molecular size range and purity of PD-1 nano antibodies are detected by 15%SDS-PAGE protein electrophoresis:SDS-PAGE electrophoresis knots Fruit is shown in 18kDa and nearby apparent band occurs, is consistent with expection;The inspection result of Western Blot proves near 18kDa The band of appearance can be combined with anti-His mAb, NbPD-1With His labels, it was demonstrated that NbPD-1By successful expression;Illustrate collection There is the enrichment of target protein in solution.6 plants of Nb in SDS-PAGE electrophoresis resultsPD-1Sample lane band is more single after purification, says Bright NbPD-1Purity is higher;Peak sample is penetrated in the inspection result of Western Blot without there is band, is purified in equilibrium process No destination protein is eluted;Illustrate that purification effect is preferable.
6.PD-1 nano antibodies concentrate
With the Amicon-Ultra-15 super filter tubes (MWCO 3kDa) of Millipore, 1 × PBS (PH7.4) is slow as washing Fliud flushing, 4 DEG C, 4 000rpm centrifugal ultrafiltrations, removal imidazo, which is concentrated into, needs volume, is preserved after 0.22 μm of degerming.
BCA methods measure antibody protein concentration, SDS-PAGE and Western Blot verification nano antibody expression, SEC-HPLC Detect nano antibody purity.
2 plants of NbPD-1Engineering bacteria yield and acquisition purity of protein are as shown in table 2.
2 Nb of tablePD-1Protein yield and purity
From the data in table 2, it can be seen that 2 plants of NbPD-1Engineering bacteria yield is more than 3.6mg/L, and purity is between 93~97%.
7.NbPD-1Physicochemical property is predicted
By using bioinformatics website ExPASy to nanoprotein sequence carry out molecular weight, theoretical isoelectric point (PI) and Overall average hydrophily (GRAVY) is analyzed, shown in table 3.
3 Nb PD-1ECD physical and chemical parameters of table are analyzed
From the data in table 3, it can be seen that NbPD-1Molecular weight is each about 18.3kDa, illustrates this expressed 2 plants of NbPD-1It is small point Son amount albumen, meets the small feature of nano antibody molecular weight.Theoretical isoelectric point (PI), NbPD-1Theoretical isoelectric point is 6.3 left in PI It is right.Overall average hydrophily (GRAVY) is the average value of all amino acid pro water numbers in finger protein, by being carried out to each amino acid It scores and obtains, the strongest Protein G RAVY of hydrophily is -4.5, and the strongest Protein G RAVY of hydrophobicity is 4.5.From hydrophobic property From the point of view of, it is determined as hydrophilic protein when GRAVY is negative value.It can thus be appreciated that 6 plants of NbPD-1It is hydrophilic protein matter.
Embodiment 4NbPD-1Physicochemical property
1.ELISA methods detect NbPD-1Specificity
It is public that CTLA4, CD4, CD8a, CD28 and the CD80 used in the present embodiment is purchased from Divine Land Yi Qiao, Beijing biotechnology Department.
Involved PD-L1 is prepared as follows to obtain in the present embodiment:According to PD-L1 gene orders (Gene ID: 29126), and pCMV (the green skies Bioisystech Co., Ltd in Shanghai) multiple cloning sites information is referred to, design primer simultaneously introduces Nhe I/Xba I restriction enzyme sites, while 6XHis labels are added.Using pReceiver-M02-PD-L1 (being purchased from reactivation gene) as mould Plate carries out PCR reactions, PCR product 1% Ago-Gel electricity using the PrimerSTAR HS DNA Polymerase of TaKaRa Swimming is examined.Using FastDigest Nhe I and the Xba I of Fermentas companies to pCMV carriers and the PD-L1 bases amplified Because carrying out double digestion, it is inserted into pCMV plasmids, the carrier for expression of eukaryon pCMV-PD-L1 of structure coding PD-L1 recombinant proteins.Pass through PCMV-PD-L1 is imported HEK 293F cells (ThermoFisher, USA) transient expression PD-L1 recombinant proteins by rotaring dyeing technology, Crude protein obtains PD-L1 recombinant proteins after Ni-NTA affinity chromatographys column purification, concentration.
(unrelated protein compares PD-1ECD recombinant proteins, PD-L1, the Enbrel for being obtained embodiment 1 using coating buffer, purchase From Pfizer, USA), CTLA4, CD4, CD8a, CD28 and CD80 be configured to final concentration of 1 μ g/mL solution respectively, with 100 μ L/ Hole is added in 96 hole elisa Plates, overnight in 4 DEG C of coatings.Next day, 0.05%PBST board-washings 2 times, the closing of 5% 37 DEG C of skim milk 2h.Respectively by the positive control PD-1mAb of a concentration of 600ng/mL (Mouse anti-PD-1antibody, purchase after board-washing 2 times From abcam), PD-1 nano antibodies (Nb2, Nb3) are added in 96 orifice plates made from blank control PBS and embodiment 2,100 μ The holes L/, 37 DEG C of incubation 1h.Primary antibody (Mouse anti-HA tag antibody are purchased from Abmart) is added after board-washing 3 times to carry out Reaction, 37 DEG C of incubation 1h.Secondary antibody is added after board-washing 3 times, and (Goat anti-mouse IgG mAb are purchased from Cell Signaling Technology), 37 DEG C of incubation 1h.TMB colour developings are added after board-washing 5 times, sulfuric acid terminates, and microplate reader measures OD450nmAnd OD630nm
Light absorption value intuitively reflects NbPD-1With the binding ability of PD-1.NbPD-1With PD-1 combine light absorption value with they and it is right It is compared according to the highest light absorption value of antigen binding, ratio is more than 3, and it is positive nano antibody to define the nano antibody.The results show that Nano antibody Nb 2 and Nb 3 and PD-1 specific binding capacities it is stronger and other 7 control antigens binding abilities it is weaker.
2.NbPD-1Affinity costant measures
The affinity costant of PD-1 nano antibodies is measured using non-competing enzyme immunoassay.
Compound concentration is the PD-1ECD of 4 kinds of various concentrations of 2 μ g/mL, 1 μ g/mL, 0.5 μ g/mL, 0.25 μ g/mL respectively Antigenic solution, with 100 holes μ L/ be added 96 hole elisa Plates in, in 4 DEG C coating overnight.Next day board-washing is simultaneously closed.It will be prepared PD-1 nano antibody degree be adjusted to 1*10-6mol/L(Nb2:18.398ug/mL Nb3:18.37669ug/mL) horizontal, 3 times times Than dilution, sample is added in 96 hole elisa Plates after board-washing 2 times, 100 holes μ L/, 37 DEG C of incubation 1h by blank control PBS.It washes Primary antibody (Mouse anti-HA tag antibody are purchased from Abmart) is added after plate 3 times to be reacted, 37 DEG C of incubation 1h.It washes Secondary antibody (Goat anti-mouse IgG mAb are purchased from Cell Signaling Technology) is added after plate 3 times, 37 DEG C incubate Educate 1h.TMB is added after board-washing 5 times to develop the color 10min, 2.29% sulfuric acid is added and terminates, microplate reader measures OD450nmAnd OD630nm。 It is fitted " S " type curve, obtains the Nb corresponding to 4 half light absorption valuesPD-1Concentration (EC50), the results are shown in Figure 2.
Nano antibody is univalent antibody, by formula KA=(n-1)/(nAb'-Ab) calculates affinity costant (Ab and Ab' in formula Indicate, when antigen concentration is Ag and Ag', to generate the antibody concentration (mol/L) of half light absorption value, n=Ag/Ag' respectively), obtain 6 A KA values calculate average value and standard deviation.The results are shown in Table 4, it is known that, Nb 2 and 3 affinity costants of Nb be respectively (2.28 ± And (4.57 ± 1.64) × 10 1.38)7L/mol。
4 Nb of tablePD-1KA values are solved to obtain after affinity determination curve simulation
3.NbPD-1Thermal stability
It is configured to the coating buffer of final concentration of 0.5 μ g/mL PD-1, is added in 96 hole elisa Plates with 100 holes μ L/, in 4 DEG C Coating is overnight.Next day, 0.05%PBST board-washings 2 times, 37 DEG C of closing 2h of 5%BSA.Sample is handled during closing:It will be a concentration of The positive control PD-1mAb and Nb of 500ng/mLPD-1Be respectively placed in 25 DEG C, 37 DEG C, 60 DEG C, 90 DEG C of four kinds of different temperatures it is lower each 0min, 10min, 30min, 60min, 120min and 180min.It is immediately placed on ice.After board-washing 2 times, by what is handled well Sample is added in 96 hole elisa Plates, 100 holes μ L/, 37 DEG C of incubation 1h.Primary antibody (Mouse anti-HA are added after board-washing 5 times Tag antibody are purchased from Abmart) it is reacted (PBS is added in PD-1mAb groups), 37 DEG C of incubation 1h.Secondary antibody is added after board-washing (Goat anti-mouse IgG mAb are purchased from Cell Signaling Technology) reacts, and it is aobvious that TMB is added after board-washing Color, microplate reader measure OD450nmAnd OD630nm
Using formula Relative activity%=Ab'/Ab × 100%, (Ab and Ab' is indicated at sample respectively in formula Generated light absorption value before reason and after processing) calculate thermostabilization relative activity, that is, antibodies bind antigen is relatively living after being heat-treated Property.
The results are shown in Figure 3, and after 60 DEG C of processing, PD-1mAb relative activities are remarkably decreased increase with time, Relative activity is close to 0% after 180min, and Nb 2 is maintained at 80% or more, Nb 3 and is maintained at 60% or more;It is handled by 90 DEG C Afterwards, PD-1mAb relative activities are remarkably decreased, and relative activity is reduced to 0% after handling 10min, and Nb 2 handles phase after 120min 0%, Nb, 3 relative activities are just down to after handling 60min to activity and drop to 0%;It can be seen that the Nb of the present inventionPD-1Relatively In common mouse monoclonal antibody, the stability in high-temperature process is better.
Embodiment 5NbPD-1Bioactivity research
1. protein labeling HRP experiments
The 250 μ L protein liquids to be marked are taken, 25 μ L reactions are added and start liquid, gently mixing.Horseradish mistake is added in mixed liquor Mixing in oxidizing ferment bottle is placed in 37 DEG C of incubator 2h.25 μ L terminator mixings are added, are placed in room temperature 1h.It is (final concentration of that glycerine is added 50%) it, saves backup for -20 DEG C.
2.NbPD-1Competitive assay
2.1NbPD-1With the competion experiment of PD-1mAb
It is configured to the coating buffer of final concentration of 0.5 μ g/mL PD-1, is added in 96 hole elisa Plates with 100 holes μ L/, in 4 DEG C Coating is overnight.Next day, 0.05%PBST board-washings 2 times, 5% 37 DEG C of skim milk close 2h.With 32000 times of mouse PD- of dilution 1mAb gradient dilutions NbPD-1, while using one plant of nano antibody (U.S. Abcam company ab218695) for rabbit igg as the moon Property control (Control), operation repetitive, nano antibody maximum concentration is 100 μ g/mL, dilutes 11 gradients, after board-washing 2 times plus Enter into 96 hole elisa Plates, 100 holes μ L/, 37 DEG C of incubation 1h.Secondary antibody (Goat anti-mouse IgG are added after board-washing 5 times MAb is purchased from Cell Signaling Technology), 37 DEG C of incubation 1h.TMB colour developings are added after board-washing 5 times, microplate reader measures OD 450nmAnd OD630nm
Nb 2 and Nb 3 distinguishes the half effective inhibition concentration for diluting 32000 times of PD-1mAb and 0.5 μ g/mL PD-1 0.55831μg/mL、0.20549μg/mL.As shown in Figure 4, with NbPD-1Concentration increases, and the binding force of PD-1mAb and PD-1 are in Reveal the trend successively decreased, illustrate that the combination epitope of this Nb 3 (Nb 2) and PD-1 is Chong Die or close with PD-1 epitopes with PD-1mAb, Either the affinity of Nb 3 and PD-1 is higher than the affinity between PD-1mAb and PD-1.Meanwhile as a result showing Nb 2 and Nb 3 In conjunction with the possible different or Nb 3 in region of PD-1 PD-1mAb and PD-1 affinity are likely lower than with PD-1 affinity.
2.2NbPD-1With the competion experiment of PD-L1
It is configured to the coating buffer of final concentration of 0.5 μ g/mL PD-1, is added in 96 hole elisa Plates with 100 holes μ L/, in 4 DEG C Coating is overnight.Next day, 0.05%PBST board-washings 2 times, 5%BSA close 2h.Nb is diluted with the PD-L1-HRP of 2.5 μ g/mLPD-1(0 ~20 μ g/mL) at respective concentration, it is added in 96 hole elisa Plates after board-washing 2 times, 100 holes μ L/, 37 DEG C of incubation 1h;It is anti-with nanometer Body ab218695 is as negative control group (Control), operation repetitive.Secondary antibody (Goat anti-mouse are added after board-washing 5 times IgG mAb are purchased from Cell Signaling Technology), 37 DEG C of incubation 1h.TMB is added after board-washing 5 times to develop the color 10min, The termination of 2.29% sulfuric acid is added, microplate reader measures OD450nmAnd OD630nm
As shown in Figure 5, as Nb 2 or 3 concentration of Nb increase, the binding force of PD-L1 and PD-1 show the trend successively decreased, Illustrate the combination epitope of this two plants of nano antibodies and PD-1 with PD-L1 is Chong Die or close with PD-1 epitopes or Nb 2, Nb 3 with The affinity of PD-1 is higher than PD-L1, and the PD-L1 that can be incorporated into the surfaces PD-1 is competed, i.e. Nb 2 or Nb 3 can effectively hinder The combination of disconnected PD-L1 and PD-1.
3.pCDH-CMV-MCS-EF1-Puro-PD-1 construction of recombinant plasmid
According to PD-1 gene orders and with reference to pCDH-CMV-MCS-EF1-Puro (be purchased from System Biosciences, USA) multiple cloning sites information, simultaneously Xba I/BamH I restriction enzyme sites are added in design primer, to clone PD-1 extracellular fragment genes Sequence;Pass through PCR amplification PD-1 genetic fragments;Xba I, BamH I double digestion PD-1 genetic fragments and pCDH-CMV-MCS- EF1-Puro;Then connection, conversion;Screening positive clone, sequence verification, last recombinant plasmid largely extract, and obtain containing PD-1 Recombinant plasmid.
4. lentivirus-mediated PD-1 genes transfect HEK 293T cells and stablize strain screening
It is based on 37 DEG C, 5%CO with DMEM/FBS cultures2Culture HEK 293T cells (are purchased from Thermo in incubator Fisher, USA), when cell density is up to 70%~80%, change plasma-free DMEM medium.By 1.5mL Opti-MEM, respectively DNA solution (7.5 μ g psPAX2,5 μ g slow virus packaging plasmids pMD2.G (being purchased from Addgene, USA) and 10 weights of the μ g containing PD-1 Group plasmid is sufficiently mixed, and is stored at room temperature 5min.
DNA/PEI mixed liquors:1.5mL Opti-MEM and 112.5 μ g PEI are added in another EP pipes, are added after being sufficiently mixed Mixing in mixed liquor 1, is stored at room temperature 15min.It is 70~80% to be in that DNA/PEI mixed liquors, which are dropped evenly to cell density, The HEK 293T cells of exponential phase.After 37 DEG C of culture 12h, 10mL DMEM/FBS culture mediums are changed to, continue to cultivate, 48h After HEK 293T cell supernatants are collected by centrifugation, through 0.45 μm of membrane filtration, conventional PEG precipitate virus particle.DMEM/FBS is trained It supports base weight to hang in HEK 293T cells of the virion addition in exponential phase, 37 DEG C, 5%CO2, cultivate 48h.Centrifugation is changed The DMEM/FBS medium cultures containing 10 μ g/mL puromycins are added in liquid.Visual cell's density changes liquid or passage, until being stablized HEK 293T/PD-1 cell strains.Western blot identify that HEK293T/PD-1 cells, control group HEK 293T do not occur Band, i.e., HEK 293T itself do not express PD-1, and specific band, i.e. HEK occur in the HEK 293T/PD-1 cells filtered out 293T/PD-1 expresses PD-1.
5. laser co-focusing identifies HEK 293T/PD-1 cells
HEK 293T/PD-1 and HEK the 293T cells of logarithmic growth phase are digested through 0.25% pancreatin, and piping and druming is resuspended extremely Single cell suspension, diluted concentration to 2 × 105cells/mL.The burnt special capsule of copolymerization is added, culture is suitable to cell density.1× PBS is added 4% paraformaldehyde and fixes 15min after cleaning 2 times.1 × PBS is added 1%BSA after cleaning 2 times and is resuspended, 37 DEG C of closings 1h.Antibody (Mouse anti-PD-1antibody (PE) are purchased from BD companies) is incubated after 1 × PBS cleanings, 37 DEG C are protected from light incubation 1h.PBST is cleaned 3 times, and DAPI solution is added and is incubated 15min.PBST is cleaned 3 times and anti-fluorescence quencher is added.Confocal fluorescent is aobvious Micro mirror detects PD-1 expressions on HEK 293T cell membranes.Focusing results are shown altogether, compared to control group HEK 293T, HEK There is apparent fluorescence in cell film location in 293T/PD-1, and HEK 293T/PD-1 cell membranes have PD-1 molecules;Illustrate HEK 293T/ PD-1 stable cell lines screen successfully.
6. streaming verifies NbPD-1It is combined with PD-1 molecules on HEK 293T/PD-1 cell membranes
To stablize the HEK 293T/PD-1 cells of expression PD-1 molecules as the Nb of the experiment material analysis present inventionPD-1With it is thin The combination situation of after birth surface PD-1 molecules is known with the nano antibody of the analysis present invention with the PD-1 molecular specificities naturally expressed Not activity.
HEK 293T/PD-1 and HEK the 293T cells of logarithmic growth phase, through 0.25% pancreatin digest, piping and druming be resuspended at Single cell suspension.Take 5 × 106Cells/ is managed, and 1 × PBS is cleaned 1 time.Each group HEK 293T/PD-1 are incubated antibody sequence:PD- 1mAb groups:Mouse anti-PD-1antibody+Goat anti-mouse IgG-FITC;2 groups of Nb:(Nb 2+Mouse anti-His antibody)+Goat anti-mouse IgG-FITC;3 groups of Nb:(Nb 3+Mouse anti-His antibody)+Goat anti-mouse IgG-FITC.Control group:HEK 293T cell+1%BSA+Goat anti-mouse IgG (FITC) 1 × PBS is added 4% paraformaldehyde and fixes 15min after cleaning 2 times.1%BSA weights are added in 1 × PBS after cleaning 3 times It is outstanding, 37 DEG C of closing 1h.It is incubated albumen/antibody by above-mentioned grouping after 1 × PBS cleanings, 37 DEG C are protected from light incubation 1h.It is incubated fluorescence antibody (Goat anti-mouse IgG-FITC) is added 100 μ L antibody diluents and is resuspended, and 37 DEG C of incubations are protected from light 1h.PBST cleanings 3 Time, 1 × PBS is resuspended, flow cytomery.
The results are shown in Figure 6, can be seen that from A, B, C, and PD-1mAb, Nb 2, Nb 3 can identify native conformation PD-1.Nb 2 and Nb, 3 groups of Mean values are respectively 50.7,46.9, essentially identical with PD-1mAb group Mean values 44.8, PD-1mAb groups Median Being worth (36.8), 2 groups of Median values (36.5) of Nb and 3 groups of Median values (37.5) of Nb, also almost the same (D in Fig. 6 is further PD-1mAb, Nb 2 in A, B, C, 3 data of Nb are overlapped comparison to present), that is, show that Nb 2 and Nb 3 has and mouse PD- 1mAb is identical, identifies the ability of cell surface PD-1, illustrates NbPD-1Middle Nb 2 and Nb 3 can specifically bind cell membrane surface PD-1 molecules.
7.PHA Activation In Vitro PBMC scale-model investigations NbPD-1Function
Using PHA (phytohemagglutin phytolectin) Activation In Vitro T cell, with IFN-γ Concentration Testing T cell activation situation, research should Nb in systemPD-1The active barrier effect of T cell is inhibited to PD-L1.
1 healthy volunteer 10~15mL of whole blood is taken, human PBMC's cell is detached using human lymphocyte separating liquid.Equilibrium liquid Twice of cleaning, RPMI 1640/FBS culture mediums are resuspended cell and count, with 5 × 104/ hole is inoculated in 96 orifice plates, per 50 μ L of hole. Corresponding culture hole is added with 25 holes μ L/ in the PHA of gradient, until final concentration is respectively 0 μ g/mL, 2.5 μ g/mL, 5 μ g/mL, 10 μ g/ mL.The good PD-L1 to final concentration of 0 μ g/mL, 5 μ g/mL, 10 μ of gradient dilution is added with 25 holes μ L/ in cultivating system simultaneously G/mL, 20 μ g/mL, 30 μ g/mL and 40 μ g/mL are placed in 37 DEG C of cell incubator culture 72h.300 × g is centrifuged in 10min harvests Clearly, the expression of IFN-γ in supernatant is measured (purchased from connection section biology) using people's IFN-γ ELISA detection kit, it is final to select It is irritaiting concentration to select 5 μ g/mL PHA, and 10 μ g/mL PD-L1 are inhibition concentration, carry out NbPD-1Active appraisal experiment.
Same method separation human PBMC's cell is simultaneously inoculated in same cell density in 96 orifice plates.Configure optimal pH A Irritaiting concentration (5 μ g/mL) and PD-L1 inhibition concentrations (10 μ g/mL) are added in corresponding hole.RPMI 1640/FBS culture mediums Dilute antibody NbPD-1It is added to final concentration of 0 μ g/mL, 1.25 μ g/mL, 2.5 μ g/mL, 5 μ g/mL, 10 μ g/mL and 20 μ g/mL Corresponding reaction system, 37 DEG C of cell incubator culture 72h are harvested supernatant and are surveyed using people's IFN-γ ELISA detection kit Determine the expression of IFN-γ in supernatant.3 healthy volunteer's whole bloods are taken to repeat to test respectively, statistical data.
The results are shown in Figure 7, and in the above inhibition system, IFN-γ concentration is all returned after adding Nb 2 or Nb 3 respectively It rises, and in certain NbPD-1Under concentration, IFN-γ concentration is with NbPD-1Concentration is increased and is increased.Illustrate under certain condition, two plants NbPD-1The state that activating T cell can be reversed to be inhibited by PD-L1, and then raise the expression of IFN-γ.Meanwhile it is dense in Nb 2 When degree is 2.5 μ g/mL (PHA+PD-L1+Nb2 groups), IFN-γ concentration highest;(the PHA+PD-L1 in 3 a concentration of 5 μ g/mL of Nb 3 groups of+Nb), IFN-γ concentration highest.
The above embodiment is a preferred embodiment of the present invention, but embodiments of the present invention are not by above-described embodiment Limitation, it is other it is any without departing from the spirit and principles of the present invention made by changes, modifications, substitutions, combinations, simplifications, Equivalent substitute mode is should be, is included within the scope of the present invention.
Sequence table
<110>Ji'nan University
<120>A kind of PD-1 nano antibodies and its cloning expression method and application
<160> 14
<170> SIPOSequenceListing 1.0
<210> 1
<211> 10
<212> PRT
<213>Artificial sequence (Artificial Sequence)
<220>
<223>PD-1 nano antibody CDR1 amino acid sequences
<400> 1
Gly Phe Thr His Leu Arg Tyr Ser Met Gly
1 5 10
<210> 2
<211> 10
<212> PRT
<213>Artificial sequence (Artificial Sequence)
<220>
<223>PD-1 nano antibody CDR1 amino acid sequences
<400> 2
Gly Leu Thr Tyr Leu Arg Tyr Ser Met Gly
1 5 10
<210> 3
<211> 7
<212> PRT
<213>Artificial sequence (Artificial Sequence)
<220>
<223>PD-1 nano antibody CDR2 amino acid sequences
<400> 3
Ile Gly Gly Asp Gly Arg Thr
1 5
<210> 4
<211> 23
<212> PRT
<213>Artificial sequence (Artificial Sequence)
<220>
<223>PD-1 nano antibody CDR3 amino acid sequences
<400> 4
Ala Ala Ala Val Leu Leu Asp Gly Ser Phe Ser Leu Leu Ala Pro Leu
1 5 10 15
Val Pro Tyr Lys Tyr Asp Tyr
20
<210> 5
<211> 23
<212> PRT
<213>Artificial sequence (Artificial Sequence)
<220>
<223>PD-1 nano antibody CDR3 amino acid sequences
<400> 5
Ala Ala Ala Val Leu Leu Asp Gly Ser Phe Ser Leu Leu Ala Pro Leu
1 5 10 15
Thr Pro Tyr Lys Tyr Asp Tyr
20
<210> 6
<211> 25
<212> PRT
<213>Artificial sequence (Artificial Sequence)
<220>
<223>PD-1 nano antibody FR1 amino acid sequences
<400> 6
Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Val Ala Ser
20 25
<210> 7
<211> 15
<212> PRT
<213>Artificial sequence (Artificial Sequence)
<220>
<223>PD-1 nano antibody FR2 amino acid sequences
<400> 7
Trp Phe Arg Gln Val Leu Asp Lys Glu Arg Glu Gly Val Ala Ala
1 5 10 15
<210> 8
<211> 15
<212> PRT
<213>Artificial sequence (Artificial Sequence)
<220>
<223>PD-1 nano antibody FR2 amino acid sequences
<400> 8
Trp Phe Arg Gln Val Pro Asp Lys Glu Arg Glu Gly Val Ala Ala
1 5 10 15
<210> 9
<211> 38
<212> PRT
<213>Artificial sequence (Artificial Sequence)
<220>
<223>PD-1 nano antibody FR3 amino acid sequences
<400> 9
Ser Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Phe Lys Asp Asn
1 5 10 15
Ala Lys Asn Thr Leu Tyr Leu Asp Met Asn Ser Leu Asn Pro Glu Asp
20 25 30
Thr Ala Met Tyr Tyr Cys
35
<210> 10
<211> 11
<212> PRT
<213>Artificial sequence (Artificial Sequence)
<220>
<223>PD-1 nano antibody FR4 amino acid sequences
<400> 10
Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser
1 5 10
<210> 11
<211> 129
<212> PRT
<213>Artificial sequence (Artificial Sequence)
<220>
<223>PD-1 nano antibody amino acid sequences
<400> 11
Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr His Leu Arg Tyr
20 25 30
Ser Met Gly Trp Phe Arg Gln Val Leu Asp Lys Glu Arg Glu Gly Val
35 40 45
Ala Ala Ile Gly Gly Asp Gly Arg Thr Ser Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Phe Lys Asp Asn Ala Lys Asn Thr Leu Tyr Leu
65 70 75 80
Asp Met Asn Ser Leu Asn Pro Glu Asp Thr Ala Met Tyr Tyr Cys Ala
85 90 95
Ala Ala Val Leu Leu Asp Gly Ser Phe Ser Leu Leu Ala Pro Leu Val
100 105 110
Pro Tyr Lys Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser
115 120 125
Ser
<210> 12
<211> 129
<212> PRT
<213>Artificial sequence (Artificial Sequence)
<220>
<223>PD-1 nano antibody amino acid sequences
<400> 12
Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Leu Thr Tyr Leu Arg Tyr
20 25 30
Ser Met Gly Trp Phe Arg Gln Val Pro Asp Lys Glu Arg Glu Gly Val
35 40 45
Ala Ala Ile Gly Gly Asp Gly Arg Thr Ser Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Phe Lys Asp Asn Ala Lys Asn Thr Leu Tyr Leu
65 70 75 80
Asp Met Asn Ser Leu Asn Pro Glu Asp Thr Ala Met Tyr Tyr Cys Ala
85 90 95
Ala Ala Val Leu Leu Asp Gly Ser Phe Ser Leu Leu Ala Pro Leu Thr
100 105 110
Pro Tyr Lys Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser
115 120 125
Ser
<210> 13
<211> 513
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<220>
<223>Encode the nucleotide sequence of PD-1 nano antibodies
<400> 13
atgaaatacc tattgcctac ggcagccgct ggattgttat tactcgcggc ccagccggcc 60
atggcccagg tgcagctgca ggagtctggg ggaggctcgg tgcaggctgg agggtctctg 120
agactctcct gtgtagcctc agggttcacc cacttgcgct actccatggg gtggttccgc 180
caggttctag ataaggagcg cgagggggtc gcagctattg gcggtgatgg taggacaagc 240
tacgcagact ccgtaaaggg ccgattcacc atcttcaaag acaacgccaa gaatactctg 300
tatctggaca tgaacagcct gaaccccgag gacactgcca tgtactactg tgcggcagcg 360
gtactcctag atggtagctt ctcgctcctg gcccctctag taccatataa gtatgactac 420
tggggccagg ggacccaggt caccgtctcc tcagcggccg catacccgta cgacgttccg 480
gactacggtt cccaccacca tcaccatcac tag 513
<210> 14
<211> 513
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<220>
<223>Encode the nucleotide sequence of PD-1 nano antibodies
<400> 14
atgaaatacc tattgcctac ggcagccgct ggattgttat tactcgcggc ccagccggcc 60
atggcccagg tgcagctgca ggagtctgga ggaggctcgg tgcaggctgg agggtctctg 120
agactctcct gtgtagcctc agggttaacc tacctgcgct actccatggg ctggttccgc 180
caggttccag ataaggagcg cgagggggtc gcagctattg gcggtgatgg taggacaagc 240
tacgcagact ccgtaaaggg ccgattcacc atcttcaaag acaacgccaa gaatactctg 300
tatctggaca tgaacagcct gaaccccgag gacactgcca tgtactactg tgcggcagcg 360
gtactcctgg atggtagctt ctcgctcctg gcccctctaa caccatataa gtatgactac 420
tggggccagg ggacccaggt caccgtctcc tcagcggccg catacccgta cgacgttccg 480
gactacggtt cccaccacca tcaccatcac tag 513

Claims (10)

1. a kind of PD-1 nano antibodies, including the Variable domain being made of framework region FR and complementary determining region CDR, feature It is, the Variable domain includes CDR1, CDR2 and CDR3 selected from the following:
(1) CDR1 shown in SEQ ID No.1 or SEQ ID No.2;
(2) CDR2 shown in SEQ ID No.3;
(3) CDR3 shown in SEQ ID No.4 or SEQ ID No.5.
2. PD-1 nano antibodies according to claim 1, which is characterized in that the Variable domain include selected from Under CDR1, CDR2 and CDR3:
(1) CDR3 shown in CDR2 and SEQ ID No.4 shown in CDR1 shown in SEQ ID No.1, SEQ ID No.3;
(2) CDR3 shown in CDR2 and SEQ ID No.5 shown in CDR1 shown in SEQ ID No.2, SEQ ID No.3.
3. PD-1 nano antibodies according to claim 1, which is characterized in that the framework region FR FR1 selected from the following, FR2, FR3 and FR4:
(1) FR1 shown in SEQ ID No.6;
(2) FR2 shown in SEQ ID No.7 or SEQ ID No.8;
(3) FR3 shown in SEQ ID No.9;
(4) FR4 shown in SEQ ID No.10.
4. PD-1 nano antibodies according to claim 1, it is characterised in that:
The amino acid sequence of the PD-1 nano antibodies is as shown in SEQ ID No.11 or SEQ ID No.12.
5. PD-1 nano antibodies according to claim 1 have at least one of following characteristics:
(1) PD-1 and PD-L1 is blocked to combine;
(2) T cell inactivated state caused by PD-L1 is reversed;
(3) inhibit tumour growth.
6. a kind of nucleic acid molecules, it is characterised in that:
Encode Claims 1 to 5 any one of them PD-1 nano antibodies.
7. a kind of recombinant expression carrier, it is characterised in that:
The recombination of nucleotide sequence containing coding Claims 1 to 5 any one of them PD-1 nano antibody amino acid sequences Expression vector.
8. a kind of host cell, it is characterised in that:
It has converted and has incorporated any one of coding Claims 1 to 5 on recombinant expression carrier or genome described in claim 7 The host cell and its progeny cell of the nucleotide sequence of the PD-1 nano antibodies.
9. the cloning expression method of Claims 1 to 5 any one of them PD-1 nano antibodies, which is characterized in that including as follows Step:
The nucleotide sequence of the coding PD-1 nano antibodies is cloned into expression vector, recombinant expression carrier is built;Again The recombinant expression carrier is transferred in expression system and is expressed;Substep purifying is carried out to destination protein, finally obtains institute The PD-1 nano antibodies stated.
10. the application of Claims 1 to 5 any one of them PD-1 nano antibodies, it is characterised in that:
The application is the application in preparing prevention and/or treating cancer drug.
CN201810002873.4A 2018-01-02 2018-01-02 PD-1 nano antibody and clone expression method and application thereof Active CN108299561B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810002873.4A CN108299561B (en) 2018-01-02 2018-01-02 PD-1 nano antibody and clone expression method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810002873.4A CN108299561B (en) 2018-01-02 2018-01-02 PD-1 nano antibody and clone expression method and application thereof

Publications (2)

Publication Number Publication Date
CN108299561A true CN108299561A (en) 2018-07-20
CN108299561B CN108299561B (en) 2020-11-13

Family

ID=62868461

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810002873.4A Active CN108299561B (en) 2018-01-02 2018-01-02 PD-1 nano antibody and clone expression method and application thereof

Country Status (1)

Country Link
CN (1) CN108299561B (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111153997A (en) * 2020-01-16 2020-05-15 佛山汉腾生物科技有限公司 anti-CTLA-4 nano antibody and application thereof in tumor treatment
CN111153998A (en) * 2020-01-16 2020-05-15 佛山汉腾生物科技有限公司 anti-CTLA-4 nano antibody and application thereof
CN111234019A (en) * 2020-01-16 2020-06-05 佛山汉腾生物科技有限公司 anti-CTLA-4 nano antibody, pharmaceutical composition and application thereof
WO2023011654A1 (en) * 2021-08-06 2023-02-09 启愈生物技术(上海)有限公司 Anti-pd-1 nanobody and application thereof
CN116023492A (en) * 2021-10-27 2023-04-28 新疆优迈生物技术有限公司 Preparation method of anti-human PDL1 nano antibody for blocking combination of PD1 and PDL1 and coding sequence thereof
WO2023116781A1 (en) * 2021-12-21 2023-06-29 博生吉医药科技(苏州)有限公司 Development of new pd1 single domain antibody
WO2023186061A1 (en) * 2022-03-31 2023-10-05 浙江特瑞思药业股份有限公司 Anti-pd-1 nanobody, use thereof and method thereof for treating disease
WO2023186121A1 (en) * 2022-04-02 2023-10-05 Biotheus Inc. Anti-cd39 nanobody and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106008714A (en) * 2016-05-24 2016-10-12 瑞阳(苏州)生物科技有限公司 Anti-human pd-1 humanized monoclonal antibody and application thereof
CN106939049A (en) * 2017-04-20 2017-07-11 苏州思坦维生物技术有限责任公司 Antagonism suppresses the antigens of people PD 1 and the monoclonal antibody of its ligand binding and preparation method and application
CN107474135A (en) * 2017-02-17 2017-12-15 广西医科大学 Anti- PD 1 nano antibody PD 1/Nb20 and preparation method and application

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106008714A (en) * 2016-05-24 2016-10-12 瑞阳(苏州)生物科技有限公司 Anti-human pd-1 humanized monoclonal antibody and application thereof
CN107474135A (en) * 2017-02-17 2017-12-15 广西医科大学 Anti- PD 1 nano antibody PD 1/Nb20 and preparation method and application
CN106939049A (en) * 2017-04-20 2017-07-11 苏州思坦维生物技术有限责任公司 Antagonism suppresses the antigens of people PD 1 and the monoclonal antibody of its ligand binding and preparation method and application

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHIJUAN LIN 等: "PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and MetaAnalysis", 《PLOS ONE》 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111153997A (en) * 2020-01-16 2020-05-15 佛山汉腾生物科技有限公司 anti-CTLA-4 nano antibody and application thereof in tumor treatment
CN111153998A (en) * 2020-01-16 2020-05-15 佛山汉腾生物科技有限公司 anti-CTLA-4 nano antibody and application thereof
CN111234019A (en) * 2020-01-16 2020-06-05 佛山汉腾生物科技有限公司 anti-CTLA-4 nano antibody, pharmaceutical composition and application thereof
CN111153997B (en) * 2020-01-16 2022-06-24 佛山汉腾生物科技有限公司 anti-CTLA-4 nano antibody and application thereof in tumor treatment
CN111234019B (en) * 2020-01-16 2022-06-24 佛山汉腾生物科技有限公司 anti-CTLA-4 nano antibody, pharmaceutical composition and application thereof
CN111153998B (en) * 2020-01-16 2022-06-24 佛山汉腾生物科技有限公司 anti-CTLA-4 nano antibody and application thereof
WO2023011654A1 (en) * 2021-08-06 2023-02-09 启愈生物技术(上海)有限公司 Anti-pd-1 nanobody and application thereof
CN116023492A (en) * 2021-10-27 2023-04-28 新疆优迈生物技术有限公司 Preparation method of anti-human PDL1 nano antibody for blocking combination of PD1 and PDL1 and coding sequence thereof
WO2023116781A1 (en) * 2021-12-21 2023-06-29 博生吉医药科技(苏州)有限公司 Development of new pd1 single domain antibody
WO2023186061A1 (en) * 2022-03-31 2023-10-05 浙江特瑞思药业股份有限公司 Anti-pd-1 nanobody, use thereof and method thereof for treating disease
WO2023186121A1 (en) * 2022-04-02 2023-10-05 Biotheus Inc. Anti-cd39 nanobody and uses thereof

Also Published As

Publication number Publication date
CN108299561B (en) 2020-11-13

Similar Documents

Publication Publication Date Title
CN108299561A (en) A kind of PD-1 nano antibodies and its cloning expression method and application
US11912770B2 (en) Blocking type PD-L1 single-domain camel antibody and application thereof
WO2016188449A1 (en) Single-domain antibody targeting cd47
CN109096395A (en) Blocking-up type CD47 nano antibody and application thereof
CN103709251B (en) Total man source anti-CD 26 antibodies and application thereof
CN110003335A (en) VHH chain of CD47 single domain antibody, CD47 single domain antibody, nucleotide sequence and kit
CN109232739B (en) anti-CD 38 nano antibody, coding gene and application
CN102746382A (en) B-cell epitope peptide of heart fatty acid binding protein (H-FABP), antibody and applications thereof
CN109369803B (en) Anti-rabies virus G protein nano antibody and application thereof
CN108892723B (en) Single-domain heavy chain antibody for detecting porcine epidemic diarrhea virus, preparation method and application
CN105085677B (en) Anti-vegf R2 source of people nano antibody NTV1 and its preparation method and application
CN111909272B (en) anti-PD-L1 nano antibody and application thereof
CN108017712A (en) A kind of peptide backbone of shark antibody sources and its application
CN101701039B (en) Variable regions of light chains and heavy chains of FMU-EPCAM-2A9 monoclonal antibodies
CN111138533B (en) Single domain antibody against hepatitis A virus and derived protein thereof
CN105820244B (en) anti-VEGF antibody
CN108148133A (en) anti-VEGF antibody
CN102702323B (en) Application of procalcitonin B cell epitope peptide fragment and monoclonal antibody thereof
CN113045662B (en) Nano antibody for specifically recognizing PD-L1 and application thereof
CN102702324B (en) Application of human procalcitonin B cell epitope peptide fragment and monoclonal antibody thereof
CN117777292A (en) Anti-integrin alpha 4 β 7 Nanobody and use thereof
CN111138532B (en) Use of single domain antibodies against hepatitis a virus
CN106188298A (en) A kind of Vsig4 nano antibody and epitope authentication method thereof and application
CN102643332B (en) Application of B cell epitope peptide of human PCT (Procalcitonin) and monoclonal antibody of B cell epitope peptide
CN106928358B (en) CD105 nano antibody Nb168

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant